Hoth Therapeutics Announces Preclinical Data For HT-KIT, With IND Filing Expected In Early 2026; Says 'HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis.'

• HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis.
• Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity.
• IND filing expected early 2026, opening pathway to first-in-human trials.

Preclinical Milestones:

• Over 80% reduction in KIT expression in vitro using cancer cell lines harboring activating KIT mutations.
• Significant inhibition of tumor growth in GIST and mast cell tumor animal models following systemic administration of HT-KIT.
• No observable off-target toxicity in liver, kidney, or bone marrow, suggesting a favorable safety profile.